Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Acetazolamide for Treatment Emergent Sleep Disordered Breathing
NCT02670096Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Jan 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of acetazolamide in central sleep apnea (CSA), sponsored by NYU Langone Health. Primary endpoints: Severity of Obstructive Sleep Apnea at 60 Days and Total lung capacity at 60 Days. Planned start Jan 2016; status: withdrawn.
02
Drugs
acetazolamide
03
Conditions
central sleep apnea (CSA)
Beyond the preview
Go deeper on NCT02670096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02670096.